Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individually adapted 177Lu-PSMA I&T therapy in metastatic castration-resistant prostate cancer
2026-527110-23-00Phase 2Authorised
- Sponsor
- Region Uppsala
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 PSMA I&T in prostate cancer (PCa), sponsored by Region Uppsala. Primary endpoint: Biochemical Progression-Free Survival (bPFS). Planned start Aug 2026; status: authorised.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2026-527110-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527110-23-00.